for european patients, synlab has both ip-10 and hbsag quantification in iu/ml available, both tests are makers of immune activation and response on both nucs or pegintf, ip-10 levels correlates with hbsag decrease and loss but on nucs better after 1 year
This paper may be relevant:
Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy
Original Research Article
George Papatheodoridis, John Goulis, Spilios Manolakopoulos, Aikaterini Margariti, Xenofon Exarchos, Georgios Kokkonis, Emilia Hadziyiannis, Christos Papaioannou, Emanuel Manesis, Dimitrios Pectasides, Evangelos Akriviadis
"In HBeAg-negative CHB patients, 4-year entecavir therapy decreases serum HBsAg levels, but the rate of decline is rather slow. Serum IP10 levels represent a promising predictor of HBsAg decline in this setting."
Please, most of the patients in this study are Greek, so results may not apply to all genotypes.
thanks for the link, i m checking also for studies on pegintf and ip-10
correlation is complicated on this unless hbvdna is undetactable from long time because hbv is able to suppress pegintf genes when activated.
so on pegintf monotherapy when endogenous intf genes were already activated ip-10 levels might be useless because hbv is already suppressing intf
while on those with no activated endogenous intf genes (high hbsag, high hbvdna, hbeag pos) and no hbv intf suppression yet both ip-10 and pegintf monotherapy might work
anyway i think that any immune modulation is wasted if hbvdna is not already undetectable because hbv is able to mutate or suppress that immune activation
In the same issue of Journal of Hepatology, there is a paper by Sinpapore scientists.
Reduction of HBV replication prolongs the early immunological response to IFNα therapy
Original Research Article
Anthony T. Tan, Long Truong Hoang, Daniel Chin, Erik Rasmussen, Uri Lopatin, Stefan Hart, Hans Bitter, Tom Chu, Lore Gruenbaum, Palani Ravindran, Hua Zhong, Ed Gane, Seng Gee Lim, Wan Cheng Chow, Pei-Jer Chen, Rosemary Petric, Antonio Bertoletti, Martin Lloyd Hibberd
It paints a very complicated relationship between hbv replication, IFNα, innate and T cell immune responses. It seems to support or explain combination therapy. Wish there are more systematic studies like this one.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.